{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:22:36Z","timestamp":1768458156337,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00415-022-11345-y","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T19:02:49Z","timestamp":1661194969000},"page":"6572-6581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study"],"prefix":"10.1007","volume":"269","author":[{"given":"Marl\u00e8ne","family":"Barnay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Duval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilhem","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Carla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0775-4625","authenticated-orcid":false,"given":"St\u00e9phane","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendal","family":"Le Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"issue":"1","key":"11345_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 4","key":"11345_CR2","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1007\/s10072-003-0081-7","volume":"24","author":"J Bayry","year":"2003","unstructured":"Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, Bellon B, Kaveri S, Kazatchkine MD (2003) Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci 24(Suppl 4):S217\u2013S221","journal-title":"Neurol Sci"},{"issue":"23","key":"11345_CR3","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017\u20132023","journal-title":"Neurology"},{"issue":"5\u20136","key":"11345_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000502818","volume":"81","author":"G Karelis","year":"2019","unstructured":"Karelis G, Balasa R, De Bleecker JL, Stuchevskaya T, Villa A, Van Damme P, Lagrange E, Heckmann JM, Nicolle M, Vilciu C, Bril V, Mondou E, Griffin R, Chen J, Henriquez W, Garcia B, Camprubi S, Ayguasanosa J (2019) A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% caprylate\/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol 81(5\u20136):223\u2013230","journal-title":"Eur Neurol"},{"issue":"11","key":"11345_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1212\/WNL.0000000000004365","volume":"89","author":"G Beecher","year":"2017","unstructured":"Beecher G, Anderson D, Siddiqi ZA (2017) Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial. Neurology 89(11):1135\u20131141","journal-title":"Neurology"},{"key":"11345_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3389\/fneur.2020.00921","volume":"11","author":"BN Putko","year":"2020","unstructured":"Putko BN, Beecher G, Siddiqi ZA (2020) Pharmacodynamic properties of subcutaneous immunoglobulin in myasthenia gravis: sub-analyses from an open-label trial. Front Neurol 11:921","journal-title":"Front Neurol"},{"issue":"Suppl 15","key":"11345_CR7","doi-asserted-by":"crossref","first-page":"N4.002","DOI":"10.1212\/WNL.92.15_supplement.N4.002","volume":"92","author":"M Dimachkie","year":"2019","unstructured":"Dimachkie M, Bril V, Levine T, Trivedi J, Silvestri N, Milind P, Saperstein D, Nations S, Katzberg H, Wolfe G, Herbelin L, Higgs K, Heim A, McVey A, Rico G, Statland JM, Barohn R, Pasnoor M (2019) Subcutaneous immunoglobulin in myasthenia gravis: results of a North American open label study (N4.002). Neurology 92(Suppl 15):N4.002","journal-title":"Neurology"},{"issue":"8","key":"11345_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159993","volume":"11","author":"PR Bourque","year":"2016","unstructured":"Bourque PR, Pringle CE, Cameron W, Cowan J, Chardon JW (2016) Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a retrospective cohort study. PLoS ONE 11(8):e0159993","journal-title":"PLoS ONE"},{"issue":"2","key":"11345_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/ene.14547","volume":"28","author":"M Alcantara","year":"2021","unstructured":"Alcantara M, Sarpong E, Barnett C, Katzberg H, Bril V (2021) Chronic immunoglobulin maintenance therapy in myasthenia gravis. Eur J Neurol 28(2):639\u2013646","journal-title":"Eur J Neurol"},{"issue":"1","key":"11345_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3988\/jcn.2018.14.1.98","volume":"14","author":"M Garnero","year":"2018","unstructured":"Garnero M, Fabbri S, Gemelli C, Benedetti L, Mancardi GL, Schenone A, Grandis M (2018) Subcutaneous immunoglobulins are a valuable treatment option in myasthenia gravis. J Clin Neurol 14(1):98\u201399","journal-title":"J Clin Neurol"},{"issue":"11","key":"11345_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/1756285617722437","volume":"10","author":"E Kovacs","year":"2017","unstructured":"Kovacs E, Danko K, Nagy-Vince M, Csiba L, Boczan J (2017) Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin. Ther Adv Neurol Disord 10(11):363\u2013366","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"11345_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1756285615584739","volume":"8","author":"MS Yoon","year":"2015","unstructured":"Yoon MS, Gold R, Kerasnoudis A (2015) Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders. Ther Adv Neurol Disord 8(4):153\u2013159","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"11345_CR13","first-page":"497","volume":"38","author":"KE Osserman","year":"1971","unstructured":"Osserman KE, Genkins G (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38(6):497\u2013537","journal-title":"Mt Sinai J Med"},{"issue":"7","key":"11345_CR14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52(7):1487\u20131489","journal-title":"Neurology"},{"issue":"1","key":"11345_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16\u201323","journal-title":"Neurology"},{"issue":"2","key":"11345_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB (2008) Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 38(2):957\u2013963","journal-title":"Muscle Nerve"},{"issue":"2","key":"11345_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/mus.25720","volume":"57","author":"A Abraham","year":"2018","unstructured":"Abraham A, Breiner A, Barnett C, Katzberg HD, Bril V (2018) The utility of a single simple question in the evaluation of patients with myasthenia gravis. Muscle Nerve 57(2):240\u2013244","journal-title":"Muscle Nerve"},{"issue":"2","key":"11345_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.923","volume":"8","author":"G Le Masson","year":"2018","unstructured":"Le Masson G, Sol\u00e9 G, Desnuelle C, Delmont E, Gauthier-Darnis M, Puget S, Durand-Zaleski I (2018) Home versus hospital immunoglobulin treatment for autoimmune neuropathies: a cost minimization analysis. Brain Behav 8(2):e00923","journal-title":"Brain Behav"},{"issue":"11","key":"11345_CR19","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1111\/trf.16078","volume":"60","author":"J Hartmann","year":"2020","unstructured":"Hartmann J, Klein HG (2020) Supply and demand for plasma-derived medicinal products\u2014a critical reassessment amid the COVID-19 pandemic. Transfusion 60(11):2748\u20132752","journal-title":"Transfusion"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11345-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11345-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11345-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:52:43Z","timestamp":1744206763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11345-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["11345"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11345-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}